Analysis and Evaluation of Smoking Treatment With Cytisine

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

65 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-03-20

Study Completion Date

2024-06-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The lack of clinical studies on the use of Cytisine in the treatment of the cessation of smoking, the need to find effective therapeutic alternatives and the opportunity to reduce costs related to the complications of cigarette smoking, represent the main reasons that led to the design of this study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effect of Cytisine Treatment for Smoking Cessation on Cardiovascular Function in Adult Smokers

NCT06885970

Smoking Cessation Arterial Stiffness Endothelial Dysfunction

RECRUITING

Cytisine for Smoking Cessation

NCT05729243

Tobacco Use Disorder Alcohol Use Disorder Smoking Cessation

UNKNOWN PHASE4

Cytisine Compared to Combination NRT in Relapsed Smokers

NCT04286295

Smoking Cessation Coronary Artery Disease

TERMINATED NA

A Single Dose-escalation Study of Cytisine in Adult Smokers

NCT03848208

Smoking Cessation

COMPLETED PHASE1

A Pharmacokinetic and Pharmacodynamic Evaluation of Cytisine in Healthy Smokers

NCT03303911

Smoking Cessation

TERMINATED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study is observational, retrospective and monocentric, and aims to evaluate patients who performed an initial pneumological examination at the Anti-Smoking Center of the National Institute Regina Elena tumors due to smoking cessation in the reference period. To such patients, affected of moderate or severe tobacco use disorder, drug therapy was prescribed with Cytisine 1.5 mg, with the aim of evaluating treatment adherence, efficacy and tolerability of Cytisine as monotherapy in the treatment of moderate or moderate tobacco use disorder serious. Responding patients will be taken into consideration for the study consecutively to the criteria established and pertaining to the Anti-Smoking Center of the National Cancer Institute Regina Elena in the period between 02/01/2023 and 11/30/2023 on first and subsequent visits controls.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Moderate or Severe Tobacco Use Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with moderate or severe tobacco use disorder.

Patients hospitalized at the IRE anti-smoking center, National Cancer Institute "Regina Elena", suffering from moderate or severe tobacco use disorder, who are prescribed pharmacological therapy with Cytisine 1.5 mg.

Cytisine 1,5 mg

Intervention Type DRUG

Administration of Cytisine as monotherapy in the treatment of moderate tobacco use disorder or serious

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cytisine 1,5 mg

Administration of Cytisine as monotherapy in the treatment of moderate tobacco use disorder or serious

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients aged \> 18 years;
* patients suffering from moderate or severe tobacco use disorder;
* prescription of pharmacological therapy with Cytisine;
* patients returned to the 1st check-up on schedule;

Exclusion Criteria

* Patients with contraindications to taking Cytisine and partial receptor agonists nicotinic cholinergics;
* Patients undergoing pharmacological or physical treatment for neoplastic pathology;
* Pregnant or breastfeeding women;
* Patients for whom specific information for objective assessments is not available;

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No